Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
B2
PD-L1 inhibition would be for the treatment of various cancers not covid. AFAIK. Happy to be corrected. Affimers can be used across a range of targets, the c19 virus is only one.
The reason money not being poured inti neutralizing is that the affimer tech needs to be proven safe. Antibody route based on existing technology is probably low hanging fruit rather than affimer. Well proven and tested in a general sense. Long term thou it’s an obvious path to follow.
But that’s a very layman’s view. Others might know better.
Gmcc thanks
FYI "Freedom to Operate
Affimer® technology is entirely unrelated to antibodies. It is based on a human protease inhibitor (Stefin A), so there is often freedom to operate in therapeutic applications where significant, well-established antibody-based intellectual property exists."
https://avacta.com/therapeutics/affimer-technology/
Hi Scarab and RK,
NCYT has benefitted from the removal of scarce reagents from their test kits, and development of a new COVID-HT test. (They are trade marked but not patented AFAIK)
This is due to the assistance of AZN, gsk and Cambridge labs, at the govnt instigation.
So why isn't the govnt suggesting that AVCT should be similarly grouped to develop the PD1 inhibitor technology, such that every effort is seen to be put into beating the virus?
Has Alistair Smith made representations to Boris, and Wood**** et al, to see how the land lies?
I know govnt are preoccupied with testing, but Affimer blocking is a permanent way forward, and might be developed well before an effective vaccine.
Of course we need to have that first in human test that is slated for end of 2020, but we should be trying everything in our power to get the project underway with govnt assistance, rather than poncing around trying to attract a suitable partner for the project.
(This must be eating up time in the boardroom by now I would think).
Feel free to share your view on this subject.
Typing on a phone, this BB using 1990 tech, how hard to have a edit function open for 5 min after posting !!!!
Sorry about typos, phone types half the words.
https://www.grandviewresearch.com/press-release/global-monoclonal-antibodies-market
Quick google re affirmer usage instead of antibody and size of market.138 billion dollars market.
Affimer as far as I know have not been used in humans, so many a slip between fork and mouth. But if the price usable....wow.
What I am wondering is if an antibody is used to bind to a molecule to treat a disease and is protected by IPR, can an affimer come in and replace it without being subject to that IPR. You would think
that half the battle is knowing which molecules to bind to for what condition.
If affimers has no restriction then I guess avacta could cherry pick the treatments they target, rather than wait fir IPR to expire (as with the pre-cision tech).
Be grateful if someone who knows could post.
I don’t think you could have high expectations as it’s truly groundbreaking, but certainly very high hopes based on progress to date. Sir Al recently commented on the current share price and felt that it reflected fair value based ignoring Covid. They’ve recently raised £48m from investors including Ruane and Sequoia Flooring. Given that was at 120p and conversations started a year ago, it’s clear there’s a lot of potential.
Yes, this is what I'm curious about. If - however unlikely - there turned out to be a problem with the covid related product, then the share price has to fall back on the Affimer products. Reading up on them, they sound like an exemplary opportunity .... if they work, although they don't seem to have held the share price much pre-covid. What's the sentiment on this.. low, medium or high confidence and why? Just trying to get a feel for risk. There's always some...
Thanks Tl. I am surprised there is not more debate on this subject.
Will ava6000 work as well in humans as it does in mice? What are the main risks factors driving performance and safety in humans?
If the risk is low (meaning ava 6000 is very likely to perform well in humans) then huge value for avct is highly probable.
Keen to hear from any experts.
Antibody treatment was nearest I could find and I think is a similar treatment to that being proposed with affimers (004). Involved in the OD-L1 (programmed cell death ligand ).
https://en.m.wikipedia.org/wiki/Nivolumab
Another question...
When testing in animals (Mice in this case) is so unquestionably favourable, does the probability of success when deploying with humans increase?
Are there any similar technologies that have been deployed to humans with no adverse / adverse effects?